Abstract
The effect of liposome encapsulation of the metabolic activation (phosphorylation) and degradation (deamination) of arabinofuranosylcytosine (Ara-C) in liver and spleen of dogs and mice was investigated. Ara-C in free or liposome-encapsulated form was administered i.v. to dogs and DBA2/CR mice bearing leukemia L1210. At various times after injection the concentration of Ara-C and Ara-C metabolites in the blood, liver and spleen was measured. It was shown that liposome encapsulation results in an increased Ara-C/arabinofuranosyluracil ratio in the liver and spleen of dogs and leukemic mice and that encapsulated Ara-C generates a sustained level of Ara-C triphosphate in the liver and spleen of leukemic mice. These results clearly indicate that 1) encapsulated Ara-C is protected against deamination in the liver, 2) encapsulated Ara-C is slowly released from liposomes in liver and spleen and 3) that liposomes may act as a local depot for Ara-C in these tissues.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
In this issue
Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
